KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

A prospective external validation of the GRade, Age, Nodes and Tumor score in the ECOG-ACRIN EA8143 PROSPER trial.

Sebastiano Buti, Se-Eun Kim, Michele Maffezzoli, Mohamad E Allaf, Giulia Claire Giudice, Giuseppe L Banna, Satoru Taguchi, Naomi B Haas, Michael A Carducci

Oncologist 31(4) oyag041

PMID41693026
PMCIDPMC12978424
DOI10.1093/oncolo/oyag041
发表日期2026-02-15
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: The GRade, Age, Nodes and Tumor (GRANT) score is one of the prognostic models recommended by international guidelines to refine recurrence risk stratification in patients with surgically treated renal cell carcinoma (RCC) and integrates age, tumor size, grade, and nodal status. In this study, we aimed to validate the GRANT score within the ECOG-ACRIN EA8143 PROSPER prospective trial. METHODS: We conducted a validation analysis of the GRANT score within the phase III randomized EA8143 PROSPER study of perioperative nivolumab in surgically treated RCC. Patients were classified into 2 risk groups, favorable (0-1 risk factors) versus unfavorable (2-4 risk factors). Relapse-free survival (RFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Model discrimination were evaluated using Harrell's C-index. RESULTS: Among 714 patients included, 58.3% were favorable and 41.7% unfavorable based on the GRANT score. Patients in the favorable group had a significantly longer median RFS (61.1 vs. 36.9 months; hazard ratio [HR]: 0.36, 95% confidence interval [CI]: 0.27-0.48, P < .001) and OS (median not reached, HR: 0.25, 95% CI: 0.15-0.42, P < .001) compared to patients in the unfavorable group. The c-index was 0.63 and 0.66 for RFS and OS, respectively. A better prognostic performance was observed among nonclear cell RCC for both RFS (HR: 0.13, 95% CI: 0.05-0.33, P < .001; c-index: 0.74) and OS (HR: 0.14, 95% CI: 0.04-0.50, P < .001; c-index 0.74). CONCLUSIONS: The GRANT score was prospectively validated in the PROSPER study, demonstrating prognostic value for both RFS and OS, especially in nonclear RCC, further supporting its use in clinical practice. Clinical trial registration number: ClinicalTrials.gov, NCT03055013.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 1

Figure 1 Kaplan–Meier curves of recurrence-free survival in the GRade, Age, Nodes and Tumor (GRANT) groups. GRANT favorable group: score 0-1; GRANT unfavorable group: score 2-4 (1 point each for: age >60 years, tumor grade >2, pT-stage ≥pT3b and pN1).

Figure_1_Kaplan_Meier_curves_of_recurrence-free_survival_in_the_GRade_Age_Nodes_and_Tumor_GRANT_groups

Recurrence-free Survival

Figure 1 · Panel Figure_1_Kaplan_Meier_curves_of_recurrence-free_survival_in_the_GRade_Age_Nodes_and_Tumor_GRANT_groups

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Figure_1_Kaplan_Meier_curves_of_recurrence-free_survival_in_the_GRade_Age_Nodes_and_Tumor_GRANT_groups 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Figure 2

Figure 2 Kaplan–Meier curves of overall survival in the GRade, Age, Nodes and Tumor (GRANT) groups. GRANT favorable group: score 0-1; GRANT unfavorable group: score 2-4 (1 point each for: age >60 years, tumor grade >2, pT-stage pT3b and pN1).

Overall_Survival

Overall Survival

Figure 2 · Panel Overall_Survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Overall_Survival 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果